Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 426,412 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 426,412 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $26.20, for a total value of $11,171,994.40. Following the sale, the director directly owned 751,411 shares of the company’s stock, valued at $19,686,968.20. This represents a 36.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN traded up $0.45 during mid-day trading on Monday, reaching $26.15. 1,317,571 shares of the company traded hands, compared to its average volume of 2,103,342. The company’s 50 day moving average price is $22.83 and its 200-day moving average price is $19.50. The firm has a market cap of $4.88 billion, a PE ratio of -7.85 and a beta of 1.07. Dyne Therapeutics, Inc. has a 52 week low of $11.65 and a 52 week high of $27.31. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, equities analysts expect that Dyne Therapeutics, Inc. will post -3.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. lifted its holdings in Dyne Therapeutics by 523.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after acquiring an additional 14,727,667 shares during the period. BlackRock Inc. purchased a new position in shares of Dyne Therapeutics during the 2nd quarter valued at approximately $275,500,000. Jupiter Topco LLC purchased a new position in shares of Dyne Therapeutics during the 2nd quarter valued at approximately $266,634,000. Vanguard Group Inc. lifted its stake in shares of Dyne Therapeutics by 14.9% in the 4th quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock valued at $219,376,000 after purchasing an additional 1,455,151 shares during the period. Finally, State Street Corp boosted its holdings in Dyne Therapeutics by 27.0% during the fourth quarter. State Street Corp now owns 6,692,745 shares of the company’s stock worth $130,910,000 after buying an additional 1,423,828 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on DYN shares. Royal Bank Of Canada boosted their target price on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, July 30th. Sanford C. Bernstein lifted their price target on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Cantor Fitzgerald started coverage on Dyne Therapeutics in a research note on Thursday, July 23rd. They set an “overweight” rating on the stock. TD Cowen assumed coverage on Dyne Therapeutics in a research report on Friday, June 26th. They set a “buy” rating on the stock. Finally, Wall Street Zen cut Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $34.42.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.